Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

More Data Are Needed For EGFR-Targeted Agents in NSCLC

February 14th 2019

Edward B. Garon, MD, discusses the landscape of EGFR-targeted therapy in non–small cell lung cancer.

Dr. Decker Discusses AEs Associated With Radiation in Lung Cancer

February 14th 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses common adverse events associated with radiation therapy in the treatment of patients with lung cancer.

Early-Stage NSCLC Is Ripe for Change

February 13th 2019

Following a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.

Dr. Brahmer on Immunotherapy Beyond PD-1/L1 in NSCLC

February 13th 2019

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the potential for immunotherapy beyond PD-1 and PD-L1 checkpoints in non–small cell lung cancer.

Wakelee Praises Progress, Points to Next Steps in NSCLC

February 12th 2019

Heather Wakelee, MD, shares insight on the current landscape of lung cancer and discussed how immunotherapy and targeted therapy can be improved for patients with non–small cell lung cancer.

Dr. Subramanian on the Future of Immunotherapy in NSCLC

February 9th 2019

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at St. Luke’s Cancer Institute, discusses the future of immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Drilon Discusses the Adoption of NGS in Lung Cancer

February 8th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses the adoption of next-generation sequencing (NGS) in lung cancer.

From One Cancer to Many: How NSCLC Treatment Has Changed in 20 Years

February 7th 2019

In the most recent decade, we have seen an acceleration of discovery in NSCLC, primarily driven by our understanding that there are many types of lung cancer.

Dr. Kujtan on Frontline Therapy for EGFR-Positive NSCLC

February 7th 2019

Lara Kujtan, MD, assistant professor at the University of Missouri–Kansas City School of Medicine, discusses frontline therapy for patients with EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Goldberg on Treatment Strategies for CNS Metastases

February 6th 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses treatment strategies for patients with non–small cell lung cancer that develop central nervous system metastases.

Padda Discusses Progress With Osimertinib and Next Steps in EGFR+ NSCLC

February 5th 2019

Sukhmani Padda, MD, discusses the practice-changing impact of osimertinib and addresses the challenges that still remain in EGFR-positive NSCLC.

EU Panel Recommends Pembrolizumab/Chemo Combo in Squamous NSCLC

February 4th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for first-line treatment with pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel in patients with metastatic squamous non–small cell lung cancer.

EU Panel Backs Frontline Atezolizumab Regimen in NSCLC

February 2nd 2019

The European Medicine’s Agency Committee for Medicinal Products for Human Use has recommended approval for the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer.

Dacomitinib Approaches EU Approval for EGFR+ NSCLC

February 2nd 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of dacomitinib for the frontline treatment of adult patients with metastatic non–small cell lung cancer with EGFR-activating mutations.

Dr. Padda on Overcoming Resistance to Osimertinib in EGFR+ NSCLC

February 1st 2019

Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, member, Stanford Cancer Institute, discusses therapy beyond osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

FDA Expands Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC

January 31st 2019

The FDA has expanded the indication for pemetrexed in combination with pembrolizumab and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK alterations.

Lung-MAP Trial Expands to Include All Patients With NSCLC

January 30th 2019

The Lung Cancer Master Protocol, known as the first precision medicine trial in lung cancer supported by the National Cancer Institute, has expanded to include patients with all types of non–small cell lung cancers.

Dr. Vallieres Discusses Future Applications for Surgery in Lung Cancer

January 30th 2019

Eric Vallieres, MD, medical director, Division of Thoracic Surgery, Swedish Cancer Institute, discusses future applications for surgery in the treatment of patients with lung cancer.

Dr. Socinski on Immunotherapy Approaches in Squamous NSCLC

January 30th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses combination versus single-agent immunotherapy in patients with squamous non–small cell lung cancer.

Using TMB and PD-L1 Together Could Guide Immunotherapy Decisions in NSCLC

January 29th 2019

Until more biomarkers are available, the use of tumor mutational burden with PD-L1 expression could help oncologists further personalize immunotherapy choices for patients with non–small cell lung cancer.